Pharmaceutical compositions for treating acid sphingomyelinase deficiency
A recombinant human acid sphingomyelinase composition, stabilized with sodium phosphate, methionine, and sucrose, addresses the treatment gap for ASMD by maintaining enzymatic activity and reducing sphingomyelin accumulation, enhancing treatment efficacy.
JP7832245B2Active Publication Date: 2026-03-17GENZYME CORP
View PDF -1 Cites 0 Cited by
Patent Information
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Filing Date
- 2024-03-14
- Publication Date
- 2026-03-17
Abstract
To provide compositions of recombinant human ASM (rhASM) for treating acid sphingomyelinase deficiency (ASMD).SOLUTION: A composition comprises a recombinant human acid sphingomyelinase, sodium phosphate, methionine, and sucrose.SELECTED DRAWING: None
Need to check novelty before this filing date? Find Prior Art